Key Metrics & Valuation
Market Cap 8.36B$
Next Earning Release 2026-05-06 00:00:00 (NA days)
Correlation to Market -26.4%
Technical Trend Trending up
Current Ratio 7.9
Return on Equity -25.9%
PEG Ratio -0.2
EV/EBITDA -10.8
EV/Revenue 0.0
EV/FCF -12.6
Price to Earning Correlation 16.9%
Total R&D (5yr % of Rev) 0.0%
Institutional Holding 12149.0%
Earnings & Cash Flow
- This quarter EPS is -61.6% related to same quarter last year.
- Annual earning is -48.2% compared to last year.
- EPS (ttm) in the last 4 quarters is trending down .
- Annual average earning surprise in the last 5 years is 7.9%.
- Earnings in the last 5 years, is trending down .
- 4.0 of the last 4 quarters had positive surprise.
EBITDA
- This quarter EBITDA is -346.2% related to same quarter last year.
- EBITDA in the last 4 quarters, is trending down.
- Annual EBITDA in the last 5 years, is trending down.
Free Cash Flow (FCF)
- This quarter FCF is -15.8% related to same quarter last year.
Revenue/Income
Revenue
- This quarter revenue is 0.0% related to same quarter last year.
Net Income
- This quarter income is -79.8% related to same quarter last year.
- Income ratio in the last 4 quarters, is trending down .
- Net income ratio in the last 5 years, is trending down .
Sentiment
News Sentiment
- Short term: 100.0% positive, 0.0% negative.
- Long term: 100.0% positive, 0.0% negative.
Short Interest
- Short ratio (Days to cover): 10.6
- Short as % of float: 10.1%
- Float share amount is trending down.
Future Estimates
Revenue 0.0%
Net Income -36.1%
EPS -36.1%
Price Target Up Side 48.3%
Company Profile
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Next earning release is on 2026-05-06 00:00:00, in NA days